Adopting New Consensus Guidelines for MRI in MS: Scott D. Newsome, DO


Following the development and publication of consensus guidelines for the use of MRI in MS, Scott D. Newsome, DO, discusses next steps in adopting and implementing protocols to improve patient care.

“It’s taken some work, but I can tell you it’s amazing, when you put the effort forward and you show people how easy it is to adopt these protocols, people are like, ‘Oh my gosh, we should’ve been doing this for years.’”

In conversation with NeurologyLive, Scott D. Newsome, DO, president, Consortium of Multiple Sclerosis Centers (CMSC), director, Neurosciences Consultation and Infusion Center at Green Spring Station, and associate professor of neurology, Johns Hopkins Medicine, spoke on the importance of adopting new consensus guidelines as a way to improve patient care and save time in early stages of MS diagnosis. 

Newsome spoke specifically about TREAT-MS, a multicenter, US-based, randomized, controlled trial aimed at identified the best treatment strategy for patients newly diagnosed with MS. Newsome further commented on the challenge in trying to streamline protocol across treatment centers; however, when discussing the benefits and ease of adoption, radiology centers are willing and eager to adopt new and uniform guidelines, he said.

The consensus guidelines represent the first time that protocol for the use of MRI in patients with MS has been internationally aligned. The new guidelines were published and developed by the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) study group; the CMSC; and the North America Imaging in Multiple Sclerosis (NAIMS) MRI Guidelines working group.

Wattjes MP, Ciccarelli O, Reich DS, et al; 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. Published online June 14, 2021. doi: 10.1016/S1474-4422(21)00095-8
Related Videos
Jessica Ailani, MD
Frederic Schaper, MD, PhD
Jaime Imitol, MD
Jason M. Davies, MD, PhD
Carolyn Bernstein, MD
Prashanth Rajarajan, MD, PhD
Mandy Alhajj, DO, James Dolbow, DO & Neel Fotedar, MD
Riley Bove, MD
© 2024 MJH Life Sciences

All rights reserved.